Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Cornea tolerates prolonged exposure to viscoadaptive
Eugene, OR-Prolonged presence of 2.3% sodium hyaluronate (Healon5, Pfizer) in the eye in association with its use for anterior chamber stabilization following trabeculectomy appears to be well-tolerated by the cornea, according to results of a study undertaken by Richard S. Hoffman, MD, and colleagues at the Oregon Eye Institute, Eugene.
Related Videos
Related Content
